ArticleReproductive sciences (Thousand Oaks, Calif.)2026
Assessing the Impact of Collagenase Clostridium histolyticum Injection on Biomechanical Properties of Uterine Fibroids and Adjacent Myometrial Tissue.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine fibroids (UF) are common benign tumors characterized by a higher collagen content compared to normal myometrium. Existing treatment options provide temporary relief or may impact fertility, underscoring the need for a fertility-preserving, non-invasive treatment alternative. This study aimed to explore the impact of collagenase Clostridium histolyticum (CCH) injection on the biomechanical properties of uterine fibroids to assess its potential as a therapeutic intervention. Between January 2018 and November 2020, 17 uterine fibroids measuring 30-50 mm in length with adjacent myometrium of 30 mm were obtained from patients undergoing hysterectomy for abnormal uterine bleeding. Each sample was divided into two halves, with one serving as a control and the other as an intervention. The control group samples were processed within 24 hours of collection, while the intervention group samples were injected with CCH at a dose normalized to tissue volume (2 mg/cm³) and incubated for 24 hours prior to mechanical testing. Tissue pieces measuring 30 mm in length, 12 mm in width, and 2-3 mm in thickness were prepared for mechanical testing. A tensile test was conducted using a tensile machine at a fixed speed rate of 10 mm/min under ambient temperature conditions. The strain measured displacement, UTS indicated the stiffness of the samples. The results were presented graphically on a stress-strain curve. In fibroid tissues, UTS decreased significantly from 1.79 ± 0.07 MPa in controls to 0.40 ± 0.04 MPa in treated samples (Δ = −1.39, P < 0.0001). Young’s Modulus reduced from 0.343 ± 0.068 MPa to 0.069 ± 0.031 MPa (Δ = −0.274, P = 0.00332). Conversely, myometrium tissues exhibited a modest reduction in UTS from 1.77 ± 0.04 MPa to 1.45 ± 0.05 MPa (Δ = −0.32, P < 0.0001), with no significant change in Young’s Modulus (0.164 ± 0.129 MPa to 0.108 ± 0.104 MPa, Δ = −0.056, P = 0.94). Elongation at rupture increased in both tissues: fibroids from 4.85 ± 0.15% to 4.96 ± 0.10% (Δ = +0.11, P = 0.78), and myometrium from 7.12 ± 0.06% to 9.01 ± 0.05% (Δ = +1.89, P < 0.0001). Collagenase treatment significantly weakened fibroids by reducing tensile strength and stiffness, while myometrium showed reduced strength but increased elongation due to apoptosis and reduced cell contractility. The results demonstrate that intrafibroid collagenase injections selectively soften fibroids without compromising the myometrium, highlighting its potential as a minimally invasive fibroid treatment option.
Indexed as
Identifiers
41703386What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.